ClinicalTrials.gov record
Completed Phase 1 Interventional

Study to Assess the Safety, Tolerability and Pharmacokinetics of Oral Brexpiprazole (OPC- 34712) in Adolescents With Schizophrenia

ClinicalTrials.gov ID: NCT02411695

Public ClinicalTrials.gov record NCT02411695. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 18, 2026, 12:35 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 1, Multicenter, Open-label, Dose-Escalation Trial to Assess the Safety, Tolerability and Pharmacokinetics of Oral Brexpiprazole (OPC- 34712) in Adolescents With Schizophrenia

Study identification

NCT ID
NCT02411695
Recruitment status
Completed
Study type
Interventional
Phase
Phase 1
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Enrollment
43 participants

Conditions and interventions

Conditions

Interventions

  • Brexpiprazole (OPC-34712) Drug

Drug

Eligibility (public fields only)

Age range
13 Years to 17 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Feb 28, 2015
Primary completion
Dec 31, 2016
Completion
Dec 31, 2016
Last update posted
Apr 27, 2026

2015 – 2017

United States locations

U.S. sites
10
U.S. states
8
U.S. cities
10
Facility City State ZIP Site status
Not listed Little Rock Arkansas 72211
Not listed Culver City California 90230
Not listed Orange California 92858
Not listed Washington D.C. District of Columbia 20016
Not listed Atlanta Georgia 30331
Not listed Marlton New Jersey 08053
Not listed Cincinnati Ohio 45219
Not listed Cleveland Ohio 44106
Not listed The Woodlands Texas 77381
Not listed Orem Utah 84058

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02411695, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Apr 27, 2026 · Synced May 18, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT02411695 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →